ART in Prevention of HIV and TB: Update on Current Research Efforts

Reuben Granich*,1, Somya Gupta1, Amitabh Suthar1, Caoimhe Smyth1, David Hoos2, Marco Vitoria1, Mariangela Bavicchi Simao2, Catherine Hankins2, Bernard Schwartlander2, Renee Ridzon3, Brigitte Bazin4, Brian Williams4, Ying-Ru Lo1, Craig McClure1, Julio Montaner6 and Gottfried Hirnschall1 on behalf of the ART in Prevention of HIV and TB Research Writing Group§


Abstract: There is considerable scientific evidence supporting the use of antiretroviral therapy (ART) in prevention of human immunodeficiency virus (HIV) and tuberculosis (TB) infections. The complex nature of the HIV and TB prevention responses, resource constraints, remaining questions about cost and feasibility, and the need to use a solid evidence base to make policy decisions, and the implementation challenges to translating trial data to operational settings require a well-organised and coordinated response to research in this area. To this end, we aimed to catalogue the ongoing and planned research activities that evaluate the impact of ART plus other interventions on the HIV- and/or TB-related morbidity and mortality, risk behaviour, HIV incidence and transmission. Using a limited search methodology, 50 projects were identified examining ART as prevention, representing 5 regions and 52 countries with a global distribution. There are 24 randomised controlled clinical trials with at least 12 large randomised individual or community cluster trials in resource-constrained settings that are in the planning and early implementation stages. There is considerable heterogeneity between studies in terms of methodology, interventions and geographical location. While the identified studies will undoubtedly advance our understanding of the efficacy and effectiveness of ART for prevention, some key questions may remain unanswered or only partially answered. The large number and wide variety of research projects emphasise the importance of this research issue and clearly demonstrate the potential for synergies, partnerships and coordination across funding agencies.

Keywords: HAART, highly active antiretroviral therapy, HIV prevention, randomised controlled trials, research activities, tuberculosis prevention.

INTRODUCTION

Antiretroviral therapy (ART) reduces mortality and morbidity related to human immunodeficiency virus (HIV) infection. The need to provide expanded access to ART is now widely accepted, and there is a pressing demand for both increased investment and more efficient use of funding in order to achieve and sustain universal access [1]. Furthermore, the World Health Organization (WHO) estimates that less than 40% of people living with HIV know their status and there is a need for expanded access to HIV testing and counseling [2] both as a prevention measure itself and also as a gateway to other HIV services including care and treatment. Although ART has considerable potential to save lives while reducing HIV transmission [3-6], without a reduction in HIV incidence it is unlikely that we will be able to meet and sustain Universal Access targets by 2015 [2]. Besides individual benefits, ART has substantial potential to enhance prevention efforts because it suppresses HIV viral load, and therefore infectiousness, of persons already infected with HIV [5,7,8]. As a result, there is increasing scientific evidence supporting the use of ART in prevention of HIV and tuberculosis (TB) as part of broader combination prevention efforts [5,6,8]. The HIV Prevention Trials Network (HPTN) 052 randomized controlled trial assessing the effect of early ART initiation on HIV incidence reduction in discordant couples announced their results early when the data and safety monitoring board found a 96% reduction in HIV transmission in the arm that received ART immediately between 550-350 CD4 cells/mm³ versus deferral of ART to < 250 cells/mm³ [9]. In addition, ART has been associated with up to a 92% reduction in the incidence of TB, both benefiting people with HIV and potentially reducing transmission to others [10,11]. Recognising these benefits, research is increasingly focusing on answering open questions regarding feasibility and cost-related issues of integrating ART into combination prevention approaches.

Current prevention efforts may reduce new infections but are unlikely to achieve sustained and widespread reduction in HIV incidence, and there have been widespread calls for intensification of prevention efforts in both scale and scope [12]. Interest in and exploration of ART in prevention has increased and there have been a number of stakeholders who have contributed to building understanding and the scientific

*Address correspondence to this author at the Antiretroviral Treatment and HIV Care, Department of HIV/AIDS, Building D, 1st Floor, Room 1005, World Health Organization, Avenue Appia 20, CH-1211, Geneva 27, Switzerland; Tel: 41 22 791 1459; Fax: 41 22 791 4834; E-mail: granichr@who.int

§Alphabetised by first name—see appendix for contact information.
New public health interventions frequently require convincing evidence and considerable time before they are implemented. For example, research on male circumcision took approximately 20 years and culminated in three definitive randomised controlled trials (RCTs) showing consistent efficacy [13-15], and a number of high HIV-burden countries have still not adopted circumcision as part of HIV prevention policy [16]. Similarly, prevention of mother-to-child transmission of HIV took years of basic science and field research before RCTs supported the use of ART to prevent transmission [17-21]. Ongoing areas of prevention research have been recently reviewed and include behavioural and biomedical approaches including HIV testing and counselling (including couples testing and counselling); ART; microbicides; pre-exposure prophylaxis; vaccines; and how best to package together these interventions for specific populations (“combination HIV prevention”) [22-26]. Additionally, medication-assisted therapy (MAT) for the treatment of co-morbid opioid and other drug and alcohol use disorders among HIV-infected persons is another form of prevention via preventing relapse to drug use thereby improving adherence to ART and decreasing HIV RNA levels [27-30]. Although biomedical interventions are more amenable to individual observational and randomised controlled trials, effective prevention strategies are rarely implemented in isolation and WHO recommends a combined approach [26, 31].

The complex nature of the HIV prevention response, resource constraints, remaining questions about cost and feasibility, and the need to use a solid evidence base to make policy decisions, and the implementation challenges to translating trial data to operational settings require a well-organised and coordinated response to research on ART in prevention of HIV and TB.

In November of 2009, WHO convened a meeting of stakeholders including researchers, HIV program managers, civil society representatives, people living with HIV, human rights experts and ethicists, donors and bilateral agencies. The meeting included over 100 experts who reviewed the evidence base for ART in prevention of HIV and TB, discussed ethical issues, and examined broad issues around the concept of ART for HIV prevention, including feasibility and acceptability, human rights and ethical implications, and research priorities [32]. In May 2011, the British Columbia Centre for Excellence in HIV/AIDS (BCCfE) with co-organizers WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the International AIDS Society, the United States (US) National Institutes of Health (NIH) and other stakeholders, hosted a meeting that focused on ART in prevention research [33]. It focused on critically reviewing research related to the secondary preventive benefit (as it relates to HIV and TB transmission) of expanding ART coverage among people living with HIV, commonly referred as “Treatment as Prevention” (TasP). Participants also discussed research priorities including a number of ongoing and planned research projects. To assist with strategic planning and future policy formulation, this article identifies and reviews selected “ART in prevention of HIV and TB” research efforts.

METHODS

We sought studies that evaluate the impact of ART plus other interventions on the HIV- and/or TB-related morbidity and mortality, risk behaviour, HIV incidence and transmission. We conducted a search on the websites of the National Library of Medicine, PubMed, NIH, HIV Prevention Trial Network (HPTN) and Clinical Trials.gov website to identify ongoing/planned research work on HIV and ART. The search strategy included the keywords “HIV and ART”, with “treatment”, “prevention”, “research”, “campaign” and “tuberculosis” alone and in combination. Out of nearly 500 studies, selected studies pertaining to evaluating the impact of ART plus other interventions on HIV- and/or TB-related morbidity and mortality, risk behaviour, HIV incidence and transmission were obtained. Community-based studies, randomised controlled trials, cohort studies and other types of studies were included. Scientific experts in this area of research, including funding agencies were contacted for information on current projects. They were asked to review the list of research projects on ART treatment in the prevention of HIV and TB to determine if the list was comprehensive and ensure all projects were relevant to the topic. The bibliographies of studies selected to be included in this article were again searched for additional references. We focused on explicit ART for prevention research studies and excluded studies that focused on other aspects of expanding ART or TB treatment (e.g. adherence, best regimens,) and published studies (e.g. HPTN 052). The following project details were extracted and summarized: focus of research, study design, primary outcome assessed, region, time period, agency and sponsors (if funded).

RESULTS

Summary of Studies

Our initial search yielded nearly 500 studies, among which 50 were taken forward for full review. Of the 50, 20 were from North America, 22 from Africa, 4 from Asia, 1 from Europe and 3 were multisite international studies. Of the 24 randomised control trials (individual or community cluster), 12 of the planned or ongoing studies were from resource-constrained settings. (See Table 1 and Figs. 1, 2).

Region: Africa

Scaling Up Treatment to Reduce Population Level Incidence of HIV/AIDS is a four-year study designed by investigators at the British Columbia Centre for Excellence in HIV/AIDS in British Columbia, Canada along with the Joint Clinical Research Centre in Uganda. This study uses a randomised step-wedge design to examine the impact of increased access to ART in Ugandan regions on incidence measured by home-based testing. Because of decreased scale-up of ART in the year 2011, this study is being re-evaluated. This study has received funding from the Canadian Institutes of Health Research.

Discordant Couples (DISCO) Cohort Team is a four-year cohort of discordant couples in central-eastern Uganda. It is a partnership between researchers at the BC Centre for Excellence in HIV/AIDS in British Columbia, Canada and The AIDS Support Organisation (TASO) in Uganda [34]. The study follows 550 HIV-uninfected individuals who are co-habiting partners of HIV-infected individuals (i.e. serodiscordant). In 260 of the couples, the HIV-infected partner will be receiving ART, this therefore being the
Table 1. List of Ongoing and Planned Research Projects on Antiretroviral Therapy (ART) in Prevention of HIV and Tuberculosis (TB)

<table>
<thead>
<tr>
<th>Project</th>
<th>Study Type</th>
<th>Focus</th>
<th>Principal Interventions</th>
<th>Outcomes</th>
<th>Region</th>
<th>Institution</th>
<th>Time Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scaling Up Treatment to Reduce Population Level Incidence of HIV/AIDS</td>
<td>Stop-wedge community level randomised trial</td>
<td>Impact of ART scale-up on HIV incidence</td>
<td>Increased access to ART</td>
<td>HIV and TB incidence, HIV- and TB-related mortality</td>
<td>Uganda</td>
<td>University of British Columbia, Joint Clinical Research Centre</td>
<td>2011-2015</td>
</tr>
<tr>
<td>Discordant Couples (DISCO) Cohort Team</td>
<td>Cohort study</td>
<td>Impact of ART on partner acquisition of HIV</td>
<td>ART for HIV positive partner</td>
<td>Risk of HIV acquisition in HIV negative partner</td>
<td>Central-eastern Uganda</td>
<td>University of British Columbia, The AIDS Support Organization</td>
<td>2009-2012</td>
</tr>
<tr>
<td>An HIV Prevention Program for Mochudi, Botswana</td>
<td>Population-based observational study</td>
<td>Implementation of effective behavioural and biomedical preventive interventions</td>
<td>Opt-out HIV testing, ART for high viral load, behaviour modification, education and male circumcision</td>
<td>HIV incidence, HIV transmission</td>
<td>Mochudi, Botswana</td>
<td>Harvard University School of Public Health, USA</td>
<td>2009-2013</td>
</tr>
<tr>
<td>PopART (Population Effects of ART) Trial</td>
<td>Randomized controlled trial</td>
<td>Preventive effects of universal testing and treatment (UTT) intervention</td>
<td>ART irrespective of CD4 cell count</td>
<td>Population-level HIV incidence</td>
<td>Malawi, Zambia</td>
<td>London School of Hygiene and Tropical Medicine, Imperial College London, UK</td>
<td>Planning Phase</td>
</tr>
<tr>
<td>TasP (Treatment as Prevention)</td>
<td>Prospective cohort study</td>
<td>Feasibility and acceptability test, link, treat and retain strategy</td>
<td>ART at CD4 count &lt; 500 cells/mm², male circumcision, and test, link, treat and retain strategy</td>
<td>HIV and TB incidence, HIV- and TB-related morbidity and mortality</td>
<td>KwaZulu-Natal, South Africa</td>
<td>Medecins Sans Frontieres (MSF)</td>
<td>2011 onwards</td>
</tr>
<tr>
<td>Sustainable East Africa Research for Community Health (SEARCH)</td>
<td>Community cluster-randomised trial</td>
<td>Health, economic and education outcomes of community health campaign providing HIV testing and treatment services</td>
<td>Annual HIV testing, ART for all CD4 cell count, streamlined care</td>
<td>HIV incidence; TB, malaria, maternal, HIV and all-cause mortality; education and economic outcomes</td>
<td>Uganda, Kenya, Tanzania</td>
<td>University of California, San Francisco, USA, International Development Research Centre (IDRC), Kenya Medical Research Institute (KEMRI)</td>
<td>2010 onwards</td>
</tr>
<tr>
<td>Ending New Infections in Swaziland: A Catalytic Model for Southern Africa</td>
<td>Population-based observational study (entire country)</td>
<td>Universal ART following concept of Treatment 2.0 within 3 years</td>
<td>ART access for 90% of people with HIV eligible for treatment</td>
<td>HIV incidence, TB incidence</td>
<td>Swaziland</td>
<td>STOP AIDS NOW!, Clinton Health Access Initiative (CHAI)</td>
<td>2011-2014</td>
</tr>
<tr>
<td>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis against TB in HIV-infected Adults (TEMPRANO Trial)</td>
<td>Randomised controlled trial</td>
<td>Benefits and risks of early ART in HIV-infected people</td>
<td>Early ART before CD4 count reaches 350 cells/mm² and 6 months of isoniaizid</td>
<td>Death (all-cause), AIDS-defining disease, non-AIDS-defining malignancy, or non-AIDS-defining invasive bacterial disease</td>
<td>Abidjan, Côte d'Ivoire</td>
<td>Université Bordeaux, France, Treichville Université hôpital, Abidjan, Côte d'Ivoire, ANRS Sponsor</td>
<td>2008-2012</td>
</tr>
<tr>
<td>Immunology and Outcomes after HAART in HIV/TB Co-infection</td>
<td>Cohort study</td>
<td>Relationship between early responses to ART and risk of death among individuals with advanced HIV disease and active TB</td>
<td>ART in advanced HIV infection</td>
<td>Risk of death in first 6 months after ART initiation</td>
<td>Gaborone, Botswana</td>
<td>University of Pennsylvania, USA</td>
<td>2009-2014</td>
</tr>
<tr>
<td>Project</td>
<td>Study Type</td>
<td>Focus</td>
<td>Principal Interventions</td>
<td>Outcomes</td>
<td>Region</td>
<td>Institution</td>
<td>Time Period</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>--------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Enhance Prevention in Couples (EPIC)</td>
<td>Randomised controlled trial</td>
<td>Effects of enhanced prevention package for serodiscordant couples</td>
<td>Early ART, counselling, male circumcision</td>
<td>Risk of HIV acquisition in HIV-negative partner</td>
<td>Lesotho</td>
<td>Columbia University Health Sciences, USA</td>
<td>2009-2013</td>
</tr>
<tr>
<td>Interventions to Decrease HIV Infectiousness in Uganda and South Africa</td>
<td>Community randomised trial</td>
<td>Effectiveness of home-based voluntary counselling and testing (VCT) platform</td>
<td>Enhanced HIV testing, behavioural interventions, effective linkages to ART and treatment of co-infections</td>
<td>Community viral load and transmission potential</td>
<td>Uganda, South Africa</td>
<td>University of Washington, USA</td>
<td>2010-2013</td>
</tr>
<tr>
<td>HIV/HAART and Pregnancy/Contraception in Rakai, Uganda</td>
<td>Community-based observational study</td>
<td>Impact of ART on decisions regarding HIV prevention, contraceptive use and pregnancy</td>
<td>ART</td>
<td>Contraceptive use, fertility outcomes, HIV risk behaviour</td>
<td>Rakai, Uganda</td>
<td>John Hopkins University, Baltimore, USA</td>
<td>2009-2012</td>
</tr>
<tr>
<td>Impact of HIV, ART and TB Genotype on Survival in Multi-drug resistant (MDR) TB</td>
<td>Cohort study</td>
<td>Impact of ART on survival in MDR TB/HIV co-infection</td>
<td>ART</td>
<td>Mortality in MDR TB/HIV co-infected people</td>
<td>South Africa</td>
<td>Albert Einstein College of Medicine, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Integrated Prevention Demonstration Campaign (IPD)</td>
<td>Campaign population-based observational study (province-wide)</td>
<td>Impact of ART on survival in MDR TB/HIV co-infection</td>
<td>ART</td>
<td>Mortality in MDR TB/HIV co-infected people</td>
<td>South Africa</td>
<td>University of Washington, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Gender-specific Combination HIV Prevention for Youth in High-Burden Settings (MP3-Youth)</td>
<td>Campaign-based approach to testing and referral to care</td>
<td>Early access to HIV testing, counselling, distribution of disease prevention commodities and referral to care</td>
<td>Prevention method uptake, adherence, risk compensation behaviour</td>
<td>HIV prevalence, feasibility of rapid mass multi-disease prevention campaign</td>
<td>Nyanza, Kenya</td>
<td>Vestergaard Frandsen, Switzerland</td>
<td>2008-ongoing</td>
</tr>
<tr>
<td>Test and Linkage to Care (TLC-IDU) Kenya</td>
<td>Step-wedge cluster-randomised trial</td>
<td>Implementation research on seek, test, treat and retain paradigm with IDUs</td>
<td>Needle exchange programme, rapid HIV testing and point of care CD4 testing, peer treatment</td>
<td>Efficacy of seek, test, treat and retain strategy</td>
<td>Kenya</td>
<td>New York University, USA and University of Nairobi, Impact Research and Development Organisation, Kenya</td>
<td>Planning Phase</td>
</tr>
<tr>
<td>Scale-up of Antiretroviral Therapy and Transmission of HIV in Southern Africa</td>
<td>Cohort study</td>
<td>Impact of large-scale testing and early ART strategy, and role of routine viral load monitoring</td>
<td>Increased ART coverage and early ART (according to WHO guidelines)</td>
<td>Community-level HIV viral load; HIV incidence</td>
<td>Botswana, Malawi, Mozambique, South Africa, Zambia, Zimbabwe</td>
<td>iDEA Southern Africa</td>
<td>2011 onwards</td>
</tr>
<tr>
<td>Swaziland HIV Incidence Measurement Survey (SHIMS)</td>
<td>Population-based study</td>
<td>Impact of HIV prevention, care and treatment activities</td>
<td>Male circumcision, ART scale-up</td>
<td>HIV incidence, sexual risk behaviours</td>
<td>Swaziland</td>
<td>Swaziland Ministry of Health, PEPFAR, CDC, International Center for AIDS Care and Treatment Programs (ICAP)</td>
<td>2011-2014</td>
</tr>
<tr>
<td>Project</td>
<td>Study Type</td>
<td>Focus</td>
<td>Principal Interventions</td>
<td>Outcomes</td>
<td>Region</td>
<td>Institution</td>
<td>Time Period</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Ability of ART Sites to Implement 2010 Adult HIV Treatment Recommendation to Treat HIV-Adults in Discordant Relationships and Determine Patient Outcomes</td>
<td>Cohort study</td>
<td>Early ART for HIV-infected adults in discordant relationship as a preventive strategy</td>
<td>ART irrespective of CD4 cell count for HIV-infected partner in discordant couple</td>
<td>New HIV infections</td>
<td>Chongwe and Mumbwa, Zambia</td>
<td>National Antiretroviral Programme, Zambia</td>
<td>2011-2012</td>
</tr>
<tr>
<td>HPTN 070: International HIV Testing and Linkage to Care and Treatment (iTLCT) Study</td>
<td>Feasibility study for a community randomised trial</td>
<td>Enhanced testing, treatment and linkage to care strategy versus standard of care in resource-limited settings</td>
<td>Home-based HIV testing, home-based TB screening, linkage to care, ART for people with high viral load</td>
<td>Feasibility of enhanced HIV and TB testing, treatment and linkage to care strategy, HIV transmission</td>
<td>Multi-site study in Africa</td>
<td>NIH, NIAID, HPTN</td>
<td>Planning Phase</td>
</tr>
<tr>
<td>Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial</td>
<td>Randomised controlled trial</td>
<td>Effectiveness of seek, test, treat model for injection drug users</td>
<td>HIV testing in drug treatment centers, referral to care and retention of people on ART in treatment</td>
<td>ART uptake, ART adherence, treatment outcomes</td>
<td>Hanoi, Vietnam</td>
<td>John Hopkins University, Baltimore, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>HIV Testing as Prevention Strategy and ART Treatment as Prevention Strategy</td>
<td>Population-based observational study (selected cities)</td>
<td>Prevention effects of ART in serodiscordant couples</td>
<td>ART for serodiscordant couples irrespective of CD4 count</td>
<td>HIV incidence among serodiscordant couples</td>
<td>China</td>
<td>National Center for AIDS/STD Control and Prevention (NCACSTD), China Center for Disease Control and Prevention (CDC), British Columbia Centre for Excellence in HIV/AIDS, Canada</td>
<td>2011 onwards</td>
</tr>
<tr>
<td>Treatment 2.0 Project in China</td>
<td>Population-based observational study (selected cities)</td>
<td>Cost and cost-effectiveness of community-based HIV testing and treatment strategies</td>
<td>Rapid HIV testing, expanded access to quality ART</td>
<td>Cost and cost-effectiveness of Treatment 2.0 project, cost and cost-effectiveness of ART for serodiscordant couples</td>
<td>Wuhan City and Xiangfang City, Hubei, China</td>
<td>NCAIDS and AIDS Care, China</td>
<td>2011 onwards</td>
</tr>
<tr>
<td>Treatment 2.0 Project in Vietnam</td>
<td>Population-based observational study (selected provinces)</td>
<td>Optimal time for ART initiation and effects of alternate service delivery systems</td>
<td>Early ART, simple service delivery system</td>
<td>HIV incidence, TB incidence, AIDS-related mortality, cost and cost-effectiveness of simple service delivery system</td>
<td>Vietnam</td>
<td>Ministry of Health, WHO, other stakeholders</td>
<td>Planning Phase</td>
</tr>
<tr>
<td>EUROPE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partners of People on ART: a New Evaluation of the Risks (PARTNER Study)</td>
<td>Observational study</td>
<td>Risk of HIV transmission in serodiscordant couples on ART who do not use condoms</td>
<td>ART, condom use</td>
<td>HIV transmission risk</td>
<td>14 European countries</td>
<td>Copenhagen HIV Programme (CHIP), Denmark and Royal Free and University College Medical School, UK</td>
<td>2011 onwards</td>
</tr>
<tr>
<td>NORTH AMERICA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Association of Highly Active Antiretroviral Therapy Coverage, Population Viral Load, and Yearly New HIV Diagnoses in British Columbia, Canada: a Population-based Study</td>
<td>Population-based observational study</td>
<td>Relation between ART coverage, HIV-1 viral load and HIV transmission</td>
<td>ART coverage, viral load, CD4 count</td>
<td>New HIV diagnoses per year</td>
<td>British Columbia, Canada</td>
<td>British Columbia Centre for Excellence in HIV/AIDS, Canada</td>
<td>2009-ongoing</td>
</tr>
<tr>
<td>Project</td>
<td>Study Type</td>
<td>Focus</td>
<td>Principal Interventions</td>
<td>Outcomes</td>
<td>Region</td>
<td>Institution</td>
<td>Time Period</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Effect of Early Versus Deferred ART for HIV on Survival</td>
<td>Observational Study</td>
<td>Survival benefits of early ART initiation for asymptomatic patients</td>
<td>ART at CD4 count &gt;350 cells/mm³ and CD4 count &gt;500 cells/mm³</td>
<td>Relative risk of death</td>
<td>United States and Canada</td>
<td>British Columbia Centre for Excellence in HIV/AIDS, Canada</td>
<td>2009-ongoing</td>
</tr>
<tr>
<td>HAART Optimism, Drug Use and Risky Sexual Behaviour among men who have sex with men (MSM) in British Columbia</td>
<td>Population-based observational study</td>
<td>Effects of expanded universal and free-of-cost ART as a preventive measure for high-risk population</td>
<td>Universal and free ART access</td>
<td>HIV risk behaviour among men who have sex with men</td>
<td>British Columbia, Canada</td>
<td>Simon Fraser University, Canada</td>
<td>2011-2016</td>
</tr>
<tr>
<td>Effect of HAART Expansion on Community Levels of HIV Viral Load and HIV Risk Behaviours among MSM in British Columbia</td>
<td>Population-based observational study</td>
<td>Effects of expanded access to ART on HIV risk behaviour and viral load</td>
<td>Universal and free ART access</td>
<td>HIV risk behaviour among MSM, HIV viral load</td>
<td>Vancouver, British Columbia, Canada</td>
<td>Simon Fraser University, Canada</td>
<td>2010-2013</td>
</tr>
<tr>
<td>Decreases in Community Viral Load are Accompanied by Reductions in New HIV Infections in San Francisco</td>
<td>Population-based observational study</td>
<td>Relation between community viral load and new HIV infections</td>
<td>Increased HIV testing, ART coverage and effectiveness</td>
<td>Annual number of newly diagnosed HIV cases</td>
<td>San Francisco, California, USA</td>
<td>San Francisco Department of Public Health, USA</td>
<td>2004-ongoing</td>
</tr>
<tr>
<td>Project HOPE (NIH CTN 0049) -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-infected Drug Users</td>
<td>Randomised controlled trial</td>
<td>Compare two approaches to improving outcomes among hospitalised substance-using HIV patients</td>
<td>1) an active patient navigator component, 2) a passive incentives/contingency management component, 3) treatment as usual</td>
<td>Viral suppression, reducing all-cause mortality, increasing linkage to and retention in HIV primary care, increasing linkage to and retention in drug abuse treatment, and reducing hospitalisations</td>
<td>Multi-site, USA</td>
<td>University of Miami Miller School of Medicine</td>
<td>Planning enrollment (12 month study, 800 patients)</td>
</tr>
<tr>
<td>TLC+ (HPTN 065): A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States</td>
<td>Community-based study</td>
<td>Feasibility of test, link-to-care and treat strategy</td>
<td>Expanded HIV testing, linkage to HIV care and viral suppression, a computer-delivered prevention for positives intervention, and surveys of patients and clinicians</td>
<td>Viral suppression</td>
<td>Washington DC, the Bronx, New York, USA</td>
<td>Columbia University and CDC, USA</td>
<td>2010-2014</td>
</tr>
<tr>
<td>A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care</td>
<td>Randomised controlled trial and cohort study</td>
<td>Efficacy of test and link-to-care strategy at community correction</td>
<td>On-site rapid HIV testing and 1-year Project Bridge</td>
<td>HIV testing, retention in care, ART initiation, HIV plasma viral load</td>
<td>Providence, Rhode Island and Baltimore, Maryland in USA</td>
<td>Friends Research Institute and The Miriam Hospital-Lifespan, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care</td>
<td>Randomised controlled trial</td>
<td>Peer-based navigation versus usual care for HIV+ released inmates</td>
<td>Individually delivered peer-based learning approach to address barriers to and facilitators of HIV care retention</td>
<td>Barriers to HIV care, linkage and retention in care, ART adherence, viral load suppression</td>
<td>Los Angeles, USA</td>
<td>University of California, Los Angeles, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Improving Linkage to HIV Care Following Release from Incarceration</td>
<td>Observational study</td>
<td>Design, implement and test monitoring strategy for HIV+ ex-inmates to improve linkage to care</td>
<td>Monitoring strategy for follow-up HIV medical care</td>
<td>Individual, community, institutional and political factors influencing linkage to care and ART outcomes</td>
<td>USA</td>
<td>Miriam Hospital, Brown University, Providence Rhode Island, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Project</td>
<td>Study Type</td>
<td>Focus</td>
<td>Principal Interventions</td>
<td>Outcomes</td>
<td>Region</td>
<td>Institution</td>
<td>Time Period</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Randomized Controlled Trial of an Augmented Test, Treat, Link, &amp; Retain Model for North Carolina and Texas Prisoners</td>
<td>Randomised controlled trial</td>
<td>Multi-component intervention programme for prisoners pre- and post-release</td>
<td>Mandatory or opt-out HIV testing, universal ART access, personalised linkage to care and support services</td>
<td>Plasma HIV RNA, HIV transmission risk behaviour, incident sexually transmitted infections (STIs), adherence to ART</td>
<td>North Carolina and Texas, USA</td>
<td>University of North Carolina, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois</td>
<td>Community-based observational study</td>
<td>Effectiveness of seek, test, treat model (STT) that begins in jail and extends into community post-release</td>
<td>Opt-out HIV testing in jails, transition case management, university-based telemedicine, incentives for retention in care and social networking</td>
<td>Community-level HIV viral load</td>
<td>Illinois, USA</td>
<td>University of Illinois, Chicago, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Seek, Test, and Treat Strategies</td>
<td>Community-based</td>
<td>Seek, test, treat model (STT) for correctional populations</td>
<td>HIV testing for high risk population, re-link to low- or no-cost treatment services, HIV testing referral for high-risk negative individuals and their networks</td>
<td>Cost and cost-effectiveness of entire STT model and its individual components</td>
<td>USA</td>
<td>Medical College of Wisconsin, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)</td>
<td>Randomised controlled trial</td>
<td>Use of information and communication tools (ICT) with discharge planning for jail detainees</td>
<td>CARE and CARE+</td>
<td>HIV viral suppression, HIV transmission behaviours and cost-effectiveness of CARE and CARE+</td>
<td>Rhode Island and Washington DC, USA</td>
<td>Miriam Hospital/Brown University, New York University, George Washington University, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Finding, Testing and Treating High-risk Probationers and Parolees with HIV</td>
<td>Randomised controlled trial</td>
<td>Community-based seek, test, treat model for drug users on probation or parole</td>
<td>Expanded HIV testing and counselling, Project Bridge</td>
<td>Proportion of eligible individuals recruited, tested and HIV risk behaviour</td>
<td>Oakland, California, USA</td>
<td>Research Triangle Institute, North Carolina, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>START Together: HIV Testing and Treatment in and after Jail</td>
<td>Randomised controlled trial</td>
<td>Efficacy of comprehensive intervention package START Together in criminal justice system</td>
<td>HIV reentry program for incarcerated populations, computer assessment and risk-reduction education, peer health navigators</td>
<td>Proportion of inmates receiving HIV testing and proportion of individuals with undetectable HIV viral load post-release</td>
<td>New York City, USA</td>
<td>National Development and Research Institutes, New York City, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Alcohol Pharmacotherapies among Released HIV+ Prisoners</td>
<td>Randomised controlled trial</td>
<td>Effect of depot-naltrexone for alcohol-dependent HIV-positive prisoners transitioning to the community</td>
<td>Medication assisted therapy - Depot-naltrexone</td>
<td>HIV-1 RNA level, CD4 count, retention in care, alcohol treatment outcome, HIV risk behaviour, adverse side effects</td>
<td>Connecticut, USA</td>
<td>Yale University, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations</td>
<td>Randomised controlled trial</td>
<td>Effect of depot-naltrexone for opioid-dependent HIV-positive prisoners transitioning to the community</td>
<td>Medication assisted therapy - Depot-naltrexone</td>
<td>HIV-1 RNA level, CD4 count, retention in care, opiate treatment outcome, HIV risk behaviour, rate of reincarceration</td>
<td>Connecticut and Massachusetts, USA</td>
<td>Yale University, USA</td>
<td>2010-2015</td>
</tr>
<tr>
<td>Peer-driven Interventions to Seek, Test and Treat Heterosexuals at High Risk for HIV (HHR)</td>
<td>To be determined</td>
<td>Peer-driven interventions to overcome barriers to seek, test, treat HHR</td>
<td>Peer-driven HIV testing and treatment</td>
<td>Efficacy of multi-level peer-driven interventions</td>
<td>New York City, USA</td>
<td>New York University, USA</td>
<td>Planning Phase</td>
</tr>
</tbody>
</table>

(Continued...)

**Table 1** contd....
variable being manipulated. The control is 290 couples where the HIV-infected partner has not yet initiated ART (CD4 count > 250 cells/mm³, WHO stage I or II). This study has received funding from the Canadian Institutes of Health Research.

An HIV Prevention Program for Mochudi in Botswana, led by Harvard School of Public Health AIDS Initiative, will determine the feasibility and acceptability of a comprehensive program of interventions, including male circumcision, with a test-and-treat strategy [35]. HIV-positive people with a CD4 cell count above 250/mm³ will be referred for ART through the public treatment to all those who test positive for HIV irrespective of CD4 cell count. Funding has not been confirmed but a decision is expected soon.

Following a pilot study in 2010, the Africa Centre for Health and Population Studies at the University of KwaZulu-Natal (Africa Centre) [37] is starting the first phase of a cluster-randomised controlled trial, Treatment-as-prevention (TasP), in rural KwaZulu-Natal, South Africa, as part of its overall research objective to test the effectiveness of interventions in reducing HIV incidence in one of the HIV-hyperendemic rural communities in Southern Africa [38]. The trial is funded by the French National Agency for Research on AIDS and Viral Hepatitis (Agence Nationale de Recherche sur le SIDA et les hepatites virales [ANRS]) and is conducted in collaboration with the University of Bordeaux, the Hôpitaux Universitaires de Genève, and the University of the Mediterranean Aix-Marseille II. The cluster-randomised trial will start in 2011 in four out of the total 32 clusters randomly assigned to either universal ART or standard of care. The primary outcome of the controlled trial is longitudinally-measured HIV incidence; secondary outcomes include the acceptability and feasibility of treatment as prevention, as well as the economic and social consequences.
**Fig. (1).** Timeline of projects on antiretroviral therapy (ART) in prevention of HIV and tuberculosis (TB).

**Note:** Figure includes studies with an available timeline—others not listed.

1. **DISCO** - Discordant Couples Cohort Team
2. **TasP** - Treatment as Prevention
3. **SEARCH** - Sustainable East Africa Research for Community Health
5. **Immunoology and Outcomes after HAART in HIV/TB co-infection**
6. **EPIC** - Enhance Prevention in Couples
7. **Multi-component, Targeted HIV Prevention for Sub-Saharan Africa: PreventionRx**
8. **Interventions to Decrease HIV Infectiousness in Uganda and South Africa**
9. **HIV/HAART and Pregnancy/Contraception in Rakai, Uganda**
10. **Impact of HIV, ART and TB Genotype on Survival in MDR TB**
11. **IPD Campaign** - Integrated Prevention Demonstration Campaign
12. **MP3-Youth** - Gender-specific Combination HIV Prevention for Youth in High-Burden Settings
13. **SHIMS** - Swaziland HIV Incidence Measurement Survey
14. **PARTNER** - Partners of people on ART: a New Evaluation of the Risks
15. **BCCfE** - British Columbia Centre for excellence in HIV/AIDS, British Columbia, Canada
   a. Effect of early versus deferred ART for HIV on survival.
   b. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
16. **HAART Optimism, Drug Use and Risky Sexual Behaviour among MSM in British Columbia**
17. **Effect of HAART Expansion on Community Levels of HIV Viral Load and HIV Risk Behaviours among MSM in British Columbia**
18. **Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco**
19. **HPTN-065, TLC+: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States**
20. **13 NIH (National Institutes of Health, USA) funded studies on HIV prevention, testing and treatment in jails**
   a. A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care
   b. Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care
   c. Improving Linkage to HIV Care Following Release from Incarceration
   d. Randomized Control Trial of an augmented test, treat, link, & retain model for North Carolina and Texas Prisoners
   e. Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois
   f. Seek, Test, and Treat Strategies
   g. CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)
   h. Finding, Testing and Treating High-risk Probationers and Parolees with HIV
   i. START Together: HIV Testing and Treatment in and after Jail
   j. Seek, Test, Treat Strategies for Vietnamese Drug Users: A Random Controlled Trial
   k. Alcohol Pharmacotherapies among Released HIV+ Prisoners
   l. Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
   m. HIV, Buprenorphine, and the Criminal Justice System
21. **START** - Strategic Timing of Antiretroviral Treatment
22. **TTEA** - Test and Treat to End AIDS
23. **REMEMBER** - The Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens study
Doctors Without Borders/Médecins Sans Frontières (MSF) is planning a pilot community-based Treatment as Prevention (TasP) project in KwaZulu-Natal, South Africa, in collaboration with the Department of Health, beginning in 2011. The program will aim to reduce HIV and TB incidence, in addition to reducing HIV- and TB-related morbidity and mortality, and to demonstrate the feasibility and acceptability of more approaches to enhanced testing, linkage to care, ART, and retention in care. Pending ethics approval, the project will offer ART for all patients with CD4 counts below 500 cells/mm$^3$ and those with CD4 counts above 500 cells/mm$^3$ if their viral load is greater than 100,000 RNA copies/mL. Combination prevention, including medical male circumcision, will be offered, and substantial efforts will be made to reduce “leakage” across the test, link, treat, and retain cascade. HIV incidence will be measured by synthetic cohort prevalence surveys at baseline and every 2-3 years.

The Sustainable East Africa Research for Community Health (SEARCH) collaboration and University of California, San Francisco are performing pilot studies and community mapping, funded by NIH and the World Bank, in preparation for a community cluster-randomised study of 40 communities to evaluate health (HIV, TB, malaria, maternal mortality), economic and education outcomes of offering treatment to all HIV-infected persons in three East African countries—Uganda, Kenya and Tanzania. Intervention communities will receive annual HIV testing during a community health campaign, and ART will be offered to all HIV-infected children and adults through streamlined care delivery systems. Resource mobilisation in underway for a target start date of November 2012 [39].

STOP AIDS NOW! and Clinton Health Access Initiative (CHAI) have been granted Euro 8.8 million for a Treatment Centered Prevention (TCP) project in Swaziland from 2011-2014 [40]. Titled Ending New HIV Infections in Swaziland: A Catalytic Model for Southern Africa, the project will ensure that at least 90% of those in need of treatment under current guidelines are on treatment by the end of 2014. The impact of universal access to treatment based on clinical and immunologic criteria on HIV incidence will be evaluated. The study will determine whether a 50% reduction in the number of new HIV infections in Swaziland is possible by 2020.

Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis against Tuberculosis in HIV-infected Adults (ANRS 12136, TEMPRANO) study is being conducted by Université de Bordeaux [41]. This randomised trial will compare the benefits and risks of initiating ART according to the WHO guidelines to the benefits and risks of initiating ART immediately among HIV-infected adults with CD4 counts >350 cells/mm$^3$ and <800 cells/mm$^3$. In this study, half the patients will also receive six-month isoniazid prophylaxis. This study, to be conducted in Côte d’Ivoire from 2008 – 2013, is sponsored by ANRS.

Immunology and Outcomes after ART in HIV/TB co-infection is a prospective cohort study by University of Pennsylvania in Gaborone, Botswana [42]. This five-year (2009-2014) project received funding from NIH. It proposes to evaluate the relationship between very early virologic and
immunologic responses to ART and risk of death in the first six months after ART initiation among adults with advanced HIV disease (CD4 count <100 cells/mm$^3$) and active TB. This study will help improve the outcomes in global ART scale-up efforts.

**Enhance Prevention in Couples (EPIC)** study was developed by Columbia University Health Sciences to address HIV transmission among discordant couples [43]. The National Institute of Allergy and Infectious Diseases (NIAID) has financed this four-year study that began in 2009. Using a randomised controlled trial and modelling exercise, it will evaluate the effect of Enhanced Prevention Package versus Standard of Care on risk of HIV acquisition in HIV-negative partners within HIV-discordant couples in Lesotho. Enhanced Prevention Package is a multi-component package that includes ART for the HIV-infected partner at threshold of <500 CD4 cells/mm$^3$ in addition to counselling and circumcision for HIV-negative male partner.

**Multi-component, targeted HIV Prevention for Sub-Saharan Africa: PreventionRx** is a four-year study by University of Washington that started in 2010 and is receiving financing from NIH [44]. Based on epidemiologic analyses and mathematical modelling of determinants of heterosexual HIV transmission in sub-Saharan Africa and potential impact of targeted preventive interventions, this study will design an evidence-based behavioural and biomedical intervention package to be delivered through a home-based voluntary counselling and testing (VCT) to highest-risk individuals. A community-randomised effectiveness trial of this prevention package (which will include interventions like ART and male circumcision) will be implemented in Eastern and Southern Africa to determine effects of interventions on population-level HIV transmission.

**Interventions to Decrease HIV Infectiousness in Uganda and South Africa** is another University of Washington project being funded by NIH for the period 2010-2013 [45]. It will start in July 2011 and build on the home-based VCT platform (HBCT-plus) in high HIV prevalence areas of Uganda and KwaZulu-Natal. The aim is to increase the knowledge of HIV-positive status with behavioural change, and reduce HIV infectiousness through effective linkages to ART and treatment of co-infections. The performance of the HBCT-plus program will be measured by impact on community viral load and transmission potential.

**HIV/HAART and Pregnancy/Contraception in Rakat, Uganda**, a Johns Hopkins University project from 2009-2012, has received funding from NIH [46]. This study seeks to test how decisions regarding HIV prevention, contraceptive use and pregnancy desires are modified by availability and use of ART and effect of ART on pregnancy outcomes, contraceptive use and HIV risk transmission.

**Impact of HIV, ART and TB Genotype on Survival in Multi-drug Resistant (MDR) TB**, a 5-year study designed by Albert Einstein College of Medicine, has received funding from NIAID starting 2010 [47]. It will take place in rural South Africa and examine the impact of ART on improving survival in MDR TB/HIV co-infection. Furthermore, the study will examine the effect of MDR TB and HIV co-treatment on outcomes for each disease.

**Integrated Prevention Demonstration Campaign (IPD)** was an innovative public health campaign organized by Vestergaard Frandsen, Kenyan Ministry of Health and Cooperative Housing Foundation (CHF) International in the Lurambi division of western Kenya in 2008 [48]. The campaign included community-based voluntary HIV testing, counselling, on-the-spot CD4 cell count and distribution of CarePack, which contained interventions like condoms and educational material. The campaign was successful in reaching 80% of the targeted population in 7 days in an area with a very poor HIV testing rate, and mean CD4 count for HIV-positives was above 560 cells/mm$^3$. All people who tested positive were referred for further care. Post-campaign studies are underway to determine the impact of easy access to HIV testing, disease prevention commodities and referral to care services on HIV incidence. Future integrated multi-disease prevention campaigns that include HIV, TB, malaria and other disease prevention research components are targeted for selected countries in sub-Saharan Africa.

**Gender-specific Combination HIV Prevention for Youth in High-Burden Settings (MP3-Youth)** is an NIH-funded study that will determine, mathematically model, and pilot evidence-based intervention prevention packages for male and female youth in western Kenya, including HIV testing and ART referrals [49]. The study is led by New York University in partnership with University of Nairobi and Impact Research and Development Organisation (RDO), a local non-governmental organization (NGO).

**Test and Linkage to Care (TLC-IDU) Kenya**. This study will provide data regarding implementation of the seek, test, treat and retain paradigm with injection drug users (IDUs) in sub-Saharan Africa. The team (led by Kenya’s National AIDS and Sexually Transmitted Infection [STI] Control Programme along with New York University) will conduct a cluster-randomised stepped wedge trial of Kenya’s planned needle exchange program, utilising rapid HIV and point of care CD4 testing and referral to peer ART case managers for people living with HIV with CD4 <350 cells/mm$^3$.

**IeDEA Southern Africa** is a large collaborative network of 23 HIV treatment sites in Botswana, Lesotho, Malawi, Mozambique, South Africa, Zambia and Zimbabwe. The current database includes 288,015 adults (251,759 on ART) and 30,470 children (24,277 on ART). The coordination and data centres of IeDEA-South Africa are located in Bern, Switzerland and Cape Town, South Africa. This observational database is used to develop an individual-based, comprehensive mathematical model of the impact of ART on HIV transmission in Southern Africa. In particular, the role of routine viral load monitoring, the impact of the new WHO guidelines and the effect of increasing ART coverage will be explored.

**Swaziland HIV Incidence Measurement Survey (SHIMS)** is designed to be a four-year, population-level HIV incidence study assessing the impact of expanded HIV prevention, care, and treatment activities in Swaziland [50]. The assessment entails two serial, short-term cohorts to estimate and compare HIV incidence rates before and after a national male circumcision campaign, ART scale-up and other prevention activities. Primary outcomes include HIV incidence rates in men and women, HIV incidence rates in circumcised and uncircumcised men, and sexual risk
behaviours in high-risk age groups of men and women. The SHIMS study is a joint endeavour of the Swaziland Ministry of Health, the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme in Swaziland, the US Centers for Disease Control and Prevention (CDC), and International Center for AIDS Care and Treatment Programs (ICAP) at Columbia University.

The Zambian Ministry of Health and key partners will implement a National Antiretroviral Programme operational research project focused on the ability of ART sites to implement 2010 adult HIV treatment recommendations to treat HIV-infected adults in discordant relationships and determine patient outcomes. Over the past decade, Zambia’s National HIV Care and Treatment Programme has expanded at a rapid pace. By end of 2010, the country had more than 450 antiretroviral care and treatment facilities, 1200 prevention of mother-to-child transmission of HIV facilities nationwide, and had enrolled more than 500,000 adults and children into long-term care, of whom 344,000 had started ART. The 2010 Zambian Adult & Adolescent HIV Treatment Guidelines include among others, the recommendation to treat all HIV-infected adults in a serodiscordant relationship irrespective of their CD4 count in an attempt to reduce the spread of HIV in the community, particularly among discordant couples. It is estimated that up to 93% of new HIV infections in Zambia occur in couples in a stable cohabiting or marriage relationship [51] resulting in discordancy contributing significantly to the spread of HIV in this population. The national programme intends to monitor the implementation of this recommendation in operational research based in two rural districts. The focus will be 1) establishing baseline data from these facilities on the number of couples being tested for HIV and what proportion are discordant; 2) using data to improve estimations regarding the proportion of new HIV infections occurring in individuals in a stable cohabiting or marriage relationship; 3) defining the linkage between counselling and testing, and enrollment into ART services and initiation of treatment for the HIV-infected person in a serodiscordant relationship; 4) evaluating the implementation of 2010 HIV treatment recommendations to treat all HIV-infected persons in a discordant relationship and its outcome at facility level; and 5) determining the HIV status of the negative partner through a defined time period for couples accepting ART for their own health as well as preventing the spread to the negative partner. The prospective, observational cohort study of adults accessing testing and counselling as well as ART services in two districts in Zambia will start in late 2011 and end in late 2012. It will use routine programmatic data from registers and electronic medical records in Chongwe and Mumbwa Districts, Zambia.

HIV Prevention Trials Network's HPTN-070, International HIV Testing, Linkage to Care and Treatment (iTLCT) study [52] is a proposed study to assess in high-prevalence African communities the feasibility of home-based HIV testing; home-based screening and diagnosis of TB in HIV-seropositive persons; strategies for linkage to care; using high plasma viral loads as a criterion for starting ART for those currently not eligible for ART based on prevailing clinical and CD4 guidelines; and estimating HIV prevalence in pregnant women aged 15-19 years attending antenatal clinics in participating communities.

Region: Asia

Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial is a project being undertaken by Johns Hopkins University in the US from the grants from NIH for the period 2010-2015 [53]. This project will intervene with injection drug users by implementing a new approach to HIV testing via drug treatment centres, promptly referring HIV-positive people to care, and retaining those individuals on ART in treatment. In addition, behavioural risk reduction interventions will be provided. Using a randomised controlled trial, effects of this seek, test, and treat strategy on ART uptake, ART adherence and treatment outcomes will be evaluated.

At the annual national AIDS meeting in February 2011, China announced efforts to implement a country-wide HIV Testing as Prevention Strategy and ART Treatment as Prevention Strategy as a part of National HIV/AIDS policy [54]. The National Center for AIDS/STD Control and Prevention (NCAIDS) in the Chinese Center for Disease Control and Prevention (China CDC) has collaborated with the British Columbia Centre for Excellence in HIV/AIDS (BCCfE) for this national programme. It is modelled on BCCfE’s work in Vancouver, British Columbia. A recently closed study, supported by Chinese Ministry of Health, implemented by NCAIDS and Fudan University, using randomised community trial study design, demonstrated that counselling and condom promotion have hardly changed HIV incidence but antiretroviral treatment of HIV infected individuals has significantly reduced HIV incidence among discordant couples in Dehong, Yunnan, China [55]. Based on the combination of results from this study, recently released HPTN 052 results and previously published literature, China has decided, in May 2011, to provide ART to some 30,000 discordant couples irrespective of CD4 count as quickly as possible. Given the uncertainty of long-term benefit and risk, an ongoing evaluation of the treating discordant couple programme will be carried out, collaborating with BCCfE, WHO, UNAIDS, and US CDC’s Global AIDS Program (GAP) in China.

Also, NCAIDS and AIDS Care China will operationalise the Treatment 2.0 strategy in Wuhan City and Xiangfang City (Hubei) from 2011 onwards, and later on in two other sites in Yunnan and Guangxi with the support of WHO, UNAIDS, the Treatment Access Campaign, CHAI and the Pangaea Global AIDS Foundation. This pilot project focuses on community-based rapid HIV testing and access to quality ART for all medically eligible HIV patients, and will evaluate the impact of expanded access to ART. As a part of the Treatment 2.0 project, NCAIDS has proposed an impact and cost-effectiveness analysis research plan. One such study on cost-effectiveness of ART on serodiscordant couples will measure the effectiveness and cost-effectiveness between a group receiving ART and a non-ART group or between pre-ART and post-ART in terms of prevention of spousal transmission.

Vietnam is currently designing a Treatment 2.0 project that will help the health ministry in planning the country's HIV strategy. The project also proposes to adopt a simple service delivery system at two pilot sites in the country and evaluate the cost-effectiveness of this new system. The
treatment for prevention component of this project will evaluate the impact of alternate ART initiation criteria on HIV incidence, TB incidence and AIDS-related mortality. The modelling output and cost data will be useful in estimating the resources needed to control HIV/AIDS in a concentrated epidemic situation.

Region: Europe

Partners of People on ART: a New Evaluation of the Risks (PARTNER) study is a collaborative effort between Royal Free and Copenhagen HIV Programme (CHIP) and has been funded by the National Institute for Health Research, United Kingdom [56]. This study was approved in 2011 and will be carried out in 55 clinics in 14 countries in Europe. It aims to study HIV-serodiscordant partnerships that report having unprotected sex, to determine the risk of HIV transmission when the HIV-positive partner on ART has plasma viral load <50 copies/mL. Also, factors responsible for non-usage of condoms and for adoption of consistent condom use will be examined. Effectiveness of ART in reducing transmission is expected to be the strongest reason for non-usage of condoms.

Region: North America

British Columbia Centre for Excellence in HIV/AIDS (BCCCE), Vancouver, Canada has concentrated efforts on mitigating the HIV epidemic in the community. It focuses on hard-to-reach populations including aboriginal peoples, injection drug users, women, and men who have sex with men. This intervention pilot project will focus on Vancouver and Prince George, British Columbia, and is designed to go beyond these two cities and to other groups. Research efforts are also directed towards HIV risk behaviour and outcomes of ART among injection drug users [57,58,59]. BCCCE’s AIDS Research Program has also focused work on ART regimens in Canada, US and sub-Saharan Africa. Some of their studies on ART include research on optimal timing of ART initiation, effect of ART on adult mortality, and relations between ART adherence and HIV-related mortality [60,61,62,63,64]. BCCCE's current research agenda focuses on Seek and Treat for Optimal Prevention of HIV/AIDS Initiative (STOP HIV/AIDS) - an initiative to evaluate the 'Treatment as Prevention' strategy in British Columbia. Key projects look at the impact of expanded ART access on HIV/AIDS-related morbidity, mortality, and HIV incidence, and the cost and cost-effectiveness of such strategies [65,66]. British Columbia Ministry of Health has provided major support for the BCCCE’s efforts to decrease HIV incidence in the community. Studies are ongoing and additional studies are slated for publication.

HAART Optimism, Drug Use and Risky Sexual Behaviour among MSM in British Columbia is a prospective study by Simon Fraser University for the period 2010-2013, being funded by Canadian Institutes of Health Research [68]. It will examine the impact of expansion of access to ART on risk behaviour among the MSM population in Greater Vancouver and on community HIV viral load as a marker of community infectivity.

San Francisco Department of Public Health, California research focuses on HIV health, treatment and prevention outcomes in San Francisco, especially among populations at risk. A community-based study titled Decreases in Community Viral Load are Accompanied by Reductions in New HIV Infections in San Francisco [69] was undertaken from 2004-2008 to determine best approaches for HIV prevention and treatment. It hypothesised and concluded that increased HIV testing and ART coverage and effectiveness were associated with decrease in community viral load and hence in new HIV infections. The department publishes data on HIV epidemiology and emerging trends of the HIV epidemic in the city. Studies on community-wide prevention programmes are ongoing to assist the department in forming sound health policies.

Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-infected Drug Users (NIH CTN 0049) is a multisite, three-arm randomised controlled trial that will compare two distinct approaches to improving outcomes among hospitalised substance-using HIV patients [70]. The study will include 800 patients at ten sites in urban centres across the US that are heavily affected by HIV, and will focus on viral suppression as the primary endpoint. In addition, the study will also determine linkage and retention in HIV primary care, linkage and retention in drug abuse treatment, and reduction in numbers of hospitalisations. Participants will be randomised to one of three groups: 1) an active patient navigator component: a strengths-based case management approach that includes motivation, physical escort to treatment, and face-to-face booster sessions; 2) a passive incentives/contingency management component to further motivate and reinforce completion of target behaviours; or 3) treatment as usual. Enrollment is pending and participants will be followed over a 12-month period.

HPTN 065: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States (TLC-Plus Study) [71] is being conducted by the HIV Prevention Trials Network (HPTN) in several communities in the US. Two communities serve as intervention communities (Washington, District of Columbia [DC] and the Bronx, New York) and four non-intervention communities (Chicago, Illinois; Houston, Texas; Miami, Florida; and Philadelphia, Pennsylvania). The purpose of the study is to evaluate the feasibility of an enhanced community-level “test, link to care, plus treat” strategy in the US [71]. The study includes the following components. Each component of the study involves an independent design but is interrelated to the other components: 1) Expanded HIV Testing component: involves social mobilisation, with targeted messaging to promote testing, and implementation of the universal offer of HIV testing in emergency departments and hospital inpatient admissions; 2) Linkage-to-Care and Viral Suppression
components: involves site randomisation to test the effectiveness of a financial incentive (FI) intervention compared with the standard of care (SOC); 3) Prevention for Positives component: uses individual randomisation to compare the SOC plus a computer-delivered intervention with the SOC and; 4) Patient and Provider Survey component: administered at specific time points during the study to assess knowledge, attitudes and practices regarding early initiation of ART and the FI interventions. This study is funded by NIH and the US CDC and is being implemented in collaboration with Columbia University and local health departments. The study period is September 2010 to February 2014.

A Randomized Controlled Trial of HIV Testing and Linkage to Care, undertaken by Friends Research Institute and The Miriam Hospital-Lifespan is being conducted in community-based corrections facilities at two sites – Providence, Rhode Island and Baltimore, Maryland in the US [72]. First, a randomised controlled trial of HIV testing will study the efficacy of on-site rapid testing at a probation/parole office versus off-site referral at a community health centre or HIV testing clinic. The second study is a randomised trial wherein all individuals identified at community corrections with HIV will be offered enrollment in a one-year intervention study to examine the ability to improve linkage into HIV care. Participants will be randomised to receive one of two conditions: 1) Project Bridge (a case management-based strategy) for one year, or 2) Treatment as Usual (referral to standard level of care). Moreover, those randomised to treatment as usual will be given an opportunity to cross over to Project Bridge if they have failed to engage in treatment during the first three months. This project has been financed by NIH for the period 2010-2015.

Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care study is being conducted by University of California, Los Angeles among HIV-positive male ex-inmates who are being released from Los Angeles County Jail system [73]. The aim of this five-year NIH-funded study is to examine the individual and structural barriers to HIV care after release from jail and to utilize a randomised design to evaluate the impact of a peer-based health system navigation intervention on linkage and retention in care, ART adherence and viral load suppression.

Miriam Hospital (Brown University, Providence, Rhode Island) is working on Improving Linkage to HIV Care Following Release from Incarceration by designing and implementing a monitoring strategy to evaluate follow-up HIV care in community post-release [74]. This study will test the clinical and epidemiological utility of this strategy and identify individual, community, institutional and political factors influencing linkage to HIV medical care during the pre- and post-release periods. The project has also received NIH grants for a five-year period starting 2010.

University of North Carolina has received a five-year NIH grant for their study Randomized Control Trial of an Augmented Test, Treat, Link, and Retain Model for North Carolina and Texas Prisoners [75]. This ongoing trial compares a comprehensive multi-component intervention that spans incarceration and release, and includes motivational interviewing and a brief link coordination based on the University of Alabama’s Project Clinic Oriented New patient Navigation to Encourage Connection to Treatment (CONNECT) model with standard discharge planning for HIV-infected prisoners. The study will be conducted in North Carolina and Texas (which combined incarcerate 15% of all those in prison in the US). Participants will be about-to-be-released inmates with suppressed plasma HIV RNA levels. The primary aim is to determine the effect of the intervention on maintaining suppression of viraemia post-release via adherence to ART and engagement in ongoing HIV care. Secondary outcomes include risk behaviour following release.

Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois is being developed by University of Illinois in the US [76]. The project has received funds from NIH for five years starting in 2010. It constructs and evaluates a seek, test, treat (STT) model that begins at entrance to jail, continues through prison and extends into the community after release. STT has five components: 1) opt-out HIV testing in jail and prison, 2) transition case management for HIV-positive persons leaving jail and prison, 3) university-based telemedicine for all state prisoners living with HIV and HIV specialty care from jail-based staff, 4) incentives to visit community-based organizations following release from jail, and 5) social network HIV testing and partner notification. The study will also evaluate the overall impact of this model on community-level HIV viral load.

Seek, Test, and Treat Strategies study is led by Center for AIDS Intervention Research, Medical College of Wisconsin, US [77]. It was one of the twelve studies to receive grants from NIH for the period 2010-2015. The study will evaluate the cost and cost-effectiveness of a comprehensive and systematically coordinated network approach of HIV testing referral. This approach will test people in a state correctional facility being released to a major metropolitan area, (re)link HIV-positive people into low- or no-cost treatment and case management services, and seek to evaluate an innovative network method of HIV testing referral to utilise high-risk HIV-negatives in the correctional system to encourage other high-risk individuals in their social network to get tested.

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC) Study is a research project being conducted by Miriam Hospital/Brown University, New York University, and George Washington University and is being supported by NIH for five years [78]. The TLC study modifies two information and communication technology-based tools, CARE and CARE+, for use among jail detainees in Rhode Island and Washington, DC. Using randomised controlled trials, this project will evaluate the effectiveness of CARE Corrections-delivered counselling to facilitate linkage to community HIV care, maintain HIV viral suppression, and decrease HIV transmission behaviours. The project will evaluate the cost-effectiveness of the CARE Corrections tools compared to standard of care services.

Finding, Testing and Treating High-risk Probationers and Parolees with HIV is a study by Research Triangle Institute to be conducted in Oakland, California [79]. It received grants from NIH in 2010 for five years. This project seeks to design and implement a community-based strategy
of HIV testing and counselling for drug users on probation or parole, and assess the efficacy of Project Bridge compared with a usual care for HIV-positive patients using a randomised controlled trial. Outcomes of interest will be the proportion of eligible individuals who are identified and recruited, accept HIV testing, have not been HIV tested in the previous six months, and report recent HIV risk behaviour.

**START Together: HIV Testing and Treatment in and after Jail** is a five-year NIH-funded project focused on HIV prevention, testing and treatment for individuals in jails [80]. It is undertaken by National Development and Research Institutes at Rikers Island facilities in New York City. **START Together** has 3 components: 1) Project START (an HIV reentry program), 2) Computer Assessment and Risk-Reduction Education and 3) Peer Health Navigators. The study seeks to test whether **START Together** increases the proportion of inmates receiving HIV testing and the proportion of individuals with undetectable HIV viral load post-release.

The use of medication-assisted therapy (MAT) to enhance ART for soon-to-be-released HIV-infected criminal justice system (CJS) populations in Connecticut and Massachusetts is the focus of two NIH-funded grants by Yale School of Medicine researchers. The main hypothesis is that the prevention of relapse to drug and alcohol use via MAT will improve linkage to care for HIV-infected released CJS populations and will lead to greater HIV viral load suppression, thereby decreasing individual morbidity as well as decreasing transmission to the uninfected public. Both studies are five-year randomised, placebo-controlled trials of extended-release naltrexone, an opioid antagonist that is approved by the US Food and Drug Administration (FDA) for the treatment of opioid and alcohol dependency, among released HIV-infected CJS populations. The first study funded by the NIH, **Alcohol Pharmacotherapies Among Released HIV+ Prisoners**, is among prisoners in Connecticut transitioning to the community with alcohol use disorders and will assess HIV treatment, alcohol treatment and HIV risk behaviour outcomes. The second study is funded by NIH as one of the twelve Seek, Test, and Treat: Addressing HIV in the Criminal Justice System sites and is entitled **Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations**. This study will take place in Massachusetts and Connecticut; HIV treatment, opioid treatment and HIV risk behaviour outcomes are examined among prisoners and jail detainees who are being released to the community. Outcomes from these studies will establish the efficacy, safety and tolerability of MAT as an effective, evidence-based treatment for opioid and alcohol dependence for released HIV+ CJS populations that can improve viral load suppression via preventing relapse to drug and alcohol use, thereby improving adherence to ART and HIV care.

**Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV (HHR)**. This study will use National HIV Behavioral Surveillance System methodology to target HHR and overcome structural barriers to HIV testing and treatment. The primary goal of the proposed study is to evaluate the efficacy of a multi-level enhanced peer-driven intervention to seek, test, treat and retain HHR in New York City.

HIV, Buprenorphine, and the Criminal Justice System is a Yale University study that received grants from NIH for 2010-2015. It focuses on incarcerated, opiate-addicted individuals transitioning back to the community from prison or jail in Washington, DC. Opioid relapse in this group is associated with decreased ART adherence, ART discontinuation, loss in viral suppression within three months post-release and increased HIV risk behaviour. The efficacy of buprenorphine to improve adherence and retention in both drug abuse treatment and HIV care, and to reduce HIV transmission will be examined in a placebo-controlled randomised clinical trial.

**Region: Global**

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)'s Strategic Timing of Antiretroviral Treatment (START) is an international randomised trial in 37 countries to determine if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their CD4 cell count is above 500 cells/mm³ rather than waiting for it to drop to 350 cells/mm³ [81]. The study plans to enroll 4000 participants by the end of 2012 and follow them through 2015. The study, which is funded primarily by NIAID, will also examine how early ART will affect chances of developing resistance to HIV medicines, quality of life, health care utilisation and the cost of medical care.

**Test & Treat to End AIDS (TTEA)** is an international group of scientists, doctors and evaluation experts that is advocating for the US congress and executive branch of the US government to adequately fund, implement and evaluate several large-scale test and treat “implementation research” projects in three or more PEPFAR countries disproportionately affected by HIV/AIDS [82]. The purpose of these “implementation research” projects would be to determine the strategy’s effectiveness (in light of the HPTN 052 results) in significantly reducing and/or eliminating HIV transmission at the population level, significantly reducing long-term pandemic costs, saving lives, and providing donors an exit strategy from having to continually fund HIV. The start date of the advocacy project is between May 1, 2011 and April 30, 2012.

The **Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)** study (ACTG 5274) is a randomised, open-label, phase IV strategy trial that will be conducted in Africa, Asia, South America, and the Caribbean in the 18 international AIDS Clinical Trials Group (ACTG) sites. This 96-week study will start in 2011 and be conducted in resource-limited settings with a high regional tuberculosis (TB) incidence (i.e. the TB incidence within the site’s expected catchment area) of more than 100 cases/100,000 population per year, a national ART programme, and documented high mortality rates among HIV-infected individuals (i.e. at least 5% overall at six months post-ART initiation). It includes participants from resource-limited settings who present with advanced HIV disease and no probable or confirmed TB, as defined in the current ACTG diagnosis appendix. Participants who are initiating ART will be randomised to one of two strategy arms: immediate, empiric TB treatment (public health approach) or local standard of care TB treatment
(individualised approach). The primary endpoint is survival status in the two arms 24 weeks after randomisation. AIDS progression (any new WHO Stage 3 or 4 condition), virologic and CD4 cell response, HIV and TB drug resistance, and safety and tolerability of and adherence to HIV and TB drugs will be evaluated, as will the cost-effectiveness of the two strategies. Patients with probable or confirmed TB at screening will be excluded. The study is funded by the NIH and primary results are expected in 2014.

**DISCUSSION**

There is considerable scientific evidence supporting the use of ART in prevention of HIV and TB and a growing number of ongoing and planned research activities in this area [9,10,83]. Using a limited search methodology we found 50 projects representing 5 regions and 52 countries examining ART in prevention with a global distribution. There are 24 randomised controlled clinical trials with at least 12 large randomised individual or community cluster trials in resource-constrained settings that are in the planning and early implementation stages. Although by definition the studies focus on using ART to prevent HIV and TB, there is considerable heterogeneity between studies in terms of methodology, interventions (e.g. ART eligibility) and geographical location. Additionally, while the identified studies will undoubtedly advance our understanding of the efficacy and effectiveness of ART for prevention, some key questions may remain unanswered or only partially answered. For example, there are only a few randomised trials in resource-constrained settings looking at the issue of when to start ART and the population impact of expanded access to earlier ART. The large number and wide variety of research projects emphasise the importance of this research issue and clearly demonstrate the potential for synergies, partnerships and coordination across funding agencies.

There is considerable urgency to find effective solutions to prevent the 7000 new HIV infections that are estimated to occur each day. While many of the research studies will provide information over the near term, many of the key trials are in the early stages and will likely take at a minimum of two to four years for preliminary results to become available. The majority of community-based studies in resource-constrained settings are observational or prospective cohort design. Although data from observational studies is of considerable value, the WHO and other guidelines development processes favour randomised controlled trials (RCT) [84-86]. The 20-year time frame from early observational to RCT data before issuing recommendations for male circumcision provides a cautionary tale regarding potential delays in the research to policy process—in this case, most likely due to policy makers requiring evidence from RCTs before changing guidelines and developing policy. Many questions specific to ART in prevention of HIV and TB are amenable to a less expensive and more rapid operational research approach that uses data from current ART expansion efforts to answer relatively simple but important questions. For example, some research groups have opted to study operational questions and impact during district- or province-wide expansion of access to ART at higher than recommended levels. The rapid expansion of ART in resource-limited settings has been accompanied by an unprecedented collection of data on a wide variety of indicators. Although our search methodology did not specifically identify them, we anticipate the publication of retrospective analyses focusing on existing program and research data. The difficulty and delays inherent in implementing RCTs will likely mean that near- and medium-term policy decisions will necessarily need to rely on observational data, often from studies implementing combination prevention approaches. Reminiscent of infection control for TB [87,88], we may be faced with recommending a combination of evidence-based interventions without being able to attribute the decrease in transmission to a single intervention. In addition, the potential benefits to individual health from taking ART at CD4 cell counts above 350 cells/mm³ may drive earlier ART use even in the absence of data from additional individual- or community-level prevention studies. Given the urgency of the situation, a blend of research methodologies that answer key questions resulting in near-, medium- and long-term evidence will likely be the most useful to policy makers, public health authorities and affected communities.

Our study had a number of limitations. While we used a standardised methodology and thorough review of listed studies, our search likely missed many planned or ongoing studies. This is particularly true for studies in the planning phase, as these sorts of efforts are often not widely publicised. The evidence base supporting the earlier use of ART to prevent TB is growing and the subject of considerable research efforts—our approach likely missed many of the ongoing and planned studies in this area. Our search was done in English which may have excluded key projects in other languages. This is evident in the lack of studies from the South American region. Additionally, it was difficult to determine from brief descriptions of some studies whether they qualified as ART in prevention of HIV and TB studies. For example, the recently halted HPTN 052 study was not included, and we also did not include any ongoing or planned modelling research as we opted to focus on empiric studies. Bias may have been introduced through our use of experts to augment our list—as they were predominantly from wealthier and English-speaking settings. Understanding the operational aspects of providing HIV testing and counselling, HIV care including ART, and retention in care is critical, and our limited approach undoubtedly excluded important research in these critical areas. Finally, although basic and behavioural sciences have made considerable contributions to our understanding of the role of ART in prevention, with a few exceptions we did not include most of these sorts of studies in our list. Despite these limitations, our list is the first of its kind and provides considerable insights into the categories, duration, and location of ongoing and planned ART in prevention HIV and TB studies. We anticipate that it will engender further discussion and are hopeful that researchers will contact us for inclusion into future updates of this review. WHO is currently collecting research protocols and concept notes; email requests can be sent to the corresponding author to share a protocol and/or for more information.
Human rights are inviolable and expansion of HIV services should be done within a human rights framework [89]. Another area that has considerable importance but that may have been missed by our approach is research on the ethical and human rights aspects of expanding HIV services. Preliminary work exploring the programmatic costs of integrated human rights and community support interventions in South Africa has previously been presented elsewhere [90], and is included in this issue of Current HIV Research (Jones et al.). Additional research is needed to explore the potential risks and benefits of human rights and community support interventions. This will be particularly important for the benefits in terms of reaching individual and public health targets, as the potential risks are better described. While voluntary HIV testing and counselling programmes reaching millions of people have been implemented worldwide, monitoring of the quality of testing programmes including the respect afforded to human rights and consequences following testing have rarely been emphasised, and little programmatic or research data have been published. Access to high quality HIV counselling and testing is a fundamental aspect of the right to health care; however, efforts to expand HIV testing to a wide range of different populations have sometimes had serious problems, including violating individual consent and failure to provide confidentiality protections [91-96]. The possibility and consequences of these abuses and efforts to criminalise HIV affects both the research ethics of the above studies, whether community-based or in closed settings [95-97], and the success of ensuring a continuum from voluntary testing to long-term adherence to treatment (see Barr et al., this issue of Current HIV Research). Although we did not identify any ongoing or planned research on this important issue, we expect that research on the risks and benefits of expanding ART with and without specific human rights and community interventions will be forthcoming.

While it is increasingly clear that ART is both life-saving and a powerful prevention intervention, there are a number of open policy questions that remain unanswered. International and national recommendations differ, with some recommending starting earlier and for HIV serodiscordant couples, while others take a more conservative approach. Key questions including when to start ART; the potential impact, feasibility, acceptability, and cost; and how to achieve improved coverage are all being actively researched. Although a few important randomised controlled trials in resource-constrained settings are in the planning or implementation stages, it is highly likely that key policy decisions will need to be made using the available near- and medium-term observational data derived from programme data or specific research studies. Despite the multiplicity of research around the broad theme of ART in prevention of HIV and TB, the numerous and potentially divergent study outcomes and the staggered timelines may challenge the ability of normative agencies and countries to issue guidance in a timely manner. WHO and UNAIDS will continue to work with key stakeholders to map outstanding research issues, encourage collaboration among researchers and the community, and foster the coordination and rapid evaluation and incorporation of new evidence into policy.

DISCLAIMER

The opinions and statements in this article are those of the authors and do not represent the official policy, endorsement or views of the World Health Organization or the National Institutes of Health.

CONFLICT OF INTEREST

None of the authors have conflicts of interest to declare.

APPENDIX

Alex Welte, Ph.D.
South African Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA)
University of Stellenbosch, Stellenbosch, South Africa, alexwelte@sun.ac.za

Alison End
Country Manager, CHAI Swaziland
Mbabane, Swaziland
aend@clintonhealthaccess.org

Ann Duerr
Fred Hutchinson Cancer Research Center
HIV Vaccine Trials Network
Seattle, WA, USA
aduerr@hvt.org

Ann Kurth, PhD, CNM
Professor, New York University College of Nursing (NYUCN)
Executive Director, NYUCN Global
New York, NY, USA
akurth@nyu.edu

Carlos del Rio, MD
AIRCPRP Program Director
Hubert Department of Global Health, Rollins School of Public Health
Atlanta, Georgia, USA
cdelrio@emory.edu

Christopher Gordon, PhD
Chief, Secondary HIV Prevention and Translational Research Branch
Associate Director for Prevention
National Institute of Mental Health
Rockville, MD, USA
cgordon1@mail.nih.gov

Connie L Celum, MD, MPH
Professor of Global Health and Medicine, Adjunct Professor of Epidemiology
Director, International Clinical Research Center
Department of Global Health, University of Washington
Seattle, WA, USA
ccelum@u.washington.edu

Curt Beckwith, MD
Professor, Dept. of Epidemiology and Public Health
University of Miami Miller School of Medicine
Miami, Florida, USA
lmetsch@med.miami.edu

Louise van Deth
Director, STOP AIDS NOW!
Amsterdam, The Netherlands
lvandeth@stopaidsnow.nl

Lytt I. Gardner
Epidemiologist
Division of HIV/AIDS, Epi Branch
Centers for Disease Control
Atlanta GA, USA
lig0@cdc.gov

Maria Mercedes Santoro, PhD
University of Rome Tor Vergata, Department of Experimental Medicine and Biochemical Sciences
Rome, Italy
santormaria@gmail.com

Marie-Louise Newell
Director
Africa Centre for Health and Population Studies
KwaZulu-Natal, South Africa
mnewell@afriacentre.ac.za

Mark Harrington
Executive Director
Treatment Action Group
New York City, NY, USA
Mark.Harrington@treatmentactiongroup.org

Michael S. Gordon, D.P.A.
Research Scientist
Friends Research Institute Inc.
Baltimore, MD, USA
mgordon@friendsresearch.org

Moupali Das, MD, MPH
Director of Research, HIV Prevention Section
San Francisco Department of Public Health
Assistant Clinical Professor of Medicine, HIV/AIDS and Infectious Diseases, San Francisco General Hospital, UCSF
San Francisco, California, USA
dasm@php.UCSF.edu

Nathan Ford
Medical co-ordinator, Medecins Sans Frontieres
Geneva, Switzerland
nathan.ford@msf.org

Navneet Garg
Chief Development Officer
Vestergaard Frandsen
Lausanne Switzerland
ng@vestergaard-frandsen.com

Olivia Keiser, PhD
University of Bern
Institute of Social and Preventive Medicine
Finkenhulweg, Bern
Switzerland
okeiser@ispm.unibe.ch

Peter Cherutich, MD, MPH
Head of HIV Prevention
National AIDS/STD Control Programme (NASCOP), Ministry of Health
Nairobi, Kenya
pcheru2000@yahoo.com

Rachel M. Cohen
Regional Executive Director
Drugs for Neglected Diseases initiative (DNDi), North America
New York, NY, USA
rcohen@dndi.org

Redonna Chandler
Branch Chief
Division of Epidemiology, Services and Prevention Research (DESPR)
National Institute on Drug Abuse, National Institutes on Health
Bethesda, MD, USA
rc274k@nih.gov

Richard Lester, MD, FRCPC
Assistant Clinical Professor
University of British Columbia, Dept. of Medicine, Division of Infectious Diseases
Vancouver, British Columbia, Canada
rlester.id@gmail.com, richard.lester@bccdc.ca

Robert Sheneberger, MD
Assistant Professor, Institute of Human Virology
University of Maryland School of Medicine
Baltimore, MD, USA
rsheneberger@ihv.umaryland.edu

Roger Tatoud
Senior Programme Manager
International HIV Clinical Trials Research Mgmt Office
Imperial College
London, UK
r.tatoud@imperial.ac.uk

Ronald Scott Braithwaite, MD
Associate Professor
Department of Medicine, New York University Langone Medical Center
New York, NY, USA
Scott.Braithwaite@nyumc.org

Sandra Springer, MD
Assistant Professor of Medicine
Yale School of Medicine
REFERENCES


Improving Linkage to HIV Care Following Release from Incarceration. Miriam Hospital, USA. Available at: http://www.labome.org/grant/0101/da/improving/linkage/improving-linkage-to-hiv-care-following-release-from-incarceration-8056374.html.


Received: July 11, 2011 Revised: August 14, 2011 Accepted: August 18, 2011